A detailed history of Credit Suisse Ag transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Credit Suisse Ag holds 19,204 shares of MLTX stock, worth $1.05 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
19,204
Previous 19,204 -0.0%
Holding current value
$1.05 Million
Previous $1.16 Million 16.82%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 08, 2024

BUY
$36.35 - $63.02 $184,185 - $319,322
5,067 Added 35.84%
19,204 $1.16 Million
Q3 2023

Nov 13, 2023

BUY
$48.35 - $61.26 $683,523 - $866,032
14,137 New
14,137 $805,000

Others Institutions Holding MLTX

About MoonLake Immunotherapeutics


  • Ticker MLTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,925,600
  • Market Cap $2.01B
  • Description
  • MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...
More about MLTX
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.